Maximizing Translational Relevance in In Vivo Pharmacology

Maximizing Translational Relevance in In Vivo Pharmacology In vivo pharmacology remains the gold standard for evaluating the efficacy and pharmacodynamics of therapeutic candidates in preclinical development. Selecting precise, clinically relevant animal models is critical for generating high-quality data and ensuring a seamless transition to clinical trials. This webinar will showcase our end-to-end, multi-species in vivo platform, leveraging NHP and murine models to support a comprehensive suite of PK/PD/Tox, efficacy, and histology assessments. Whether you’re developing mAbs, bsAbs, ADCs, or novel modalities, this session will equip you with practical insights to refine study design, mitigate risks, and streamline the path to clinical success. In this webinar, you will learn: • Rational study design to align preclinical models with human disease biology • Key considerations for selecting optimal species and models that maximize translational relevance of PK/PD and efficacy • Data interpretation to extract actionable insights from complex pharmacodynamic and histological datasets • Proactive troubleshooting to overcome preclinical challenges and accelerate timelines This webinar provides an in-depth overview of in vivo pharmacology to enhance translational relevance in biologics discovery and development. It will cover a fit-for-purpose PK/PD/toxicology platform for modalities such as ADCs, TCEs, and Fc-engineered antibodies, with a focus on selecting tailored methods and interpreting complex datasets. The session will also introduce a streamlined NHP PK/PD/toxicology platform that enables zero lead time from antibody expression to preclinical studies. Additionally, it will introduce expert tips for model selection among diverse animal models with different levels of immune competence, and cover rationally designed CDX/PBMC models specifically for ADC and TCE characterization. In vivo pharmacology remains the gold standard for evaluating the efficacy and pharmacodynamics of therapeutic candidates in preclinical development. Selecting precise, clinically relevant animal models is critical for generating high-quality data and ensuring a seamless transition to clinical trials. In this webinar, our expert speaker will discuss how to select non-human primate and murine models to maximize translational relevance in in vivo pharmacology for therapeutic candidates, particularly modalities such as antibody–drug conjugates, T-cell engagers, and Fc-engineered antibodies. Zhili Yao, Ph.D. Director of CRO Services WuXi Biologics Dr. Zhili Yao is the Director of the In Vivo Pharmacology Group in WuXi Biologics’ CRO Services Department. He earned his degree from the Department of Chemistry and Biochemistry at Ohio State University, followed by three years of training as immunologist at the Wexner Medical Center. With over 10 years’ experience in macromolecular PK/PD/Tox platforms and oncology & autoimmune disease models, Dr. Yao played a key role in establishing the NHP toxicokinetics platform and the murine antibody biodistribution platform. Dr. Yao has also led the in vivo studies for multiple key IND projects, several of which have successfully advanced to the clinical stage.